 |
10 Diseases |  |
5 Trials |
|
5 Trials |  |
1130 News |  |
| «12345678910111213» |
- | Journal: Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. (Pubmed Central) - Jul 15, 2017
This concept is supported by prostate cancer clinical studies with sipuleucel-T, PSA-TRICOM, and ipilimumab. We discuss antigen spread with cancer immunotherapy and its implications for clinical outcomes.
- Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Tumor cell, Metastases: CTC Immune Checkpoint (clinicaltrials.gov) - Jul 13, 2017
P=N/A, N=40, Recruiting, Sponsor: Duke University
We discuss antigen spread with cancer immunotherapy and its implications for clinical outcomes. Trial primary completion date: Jan 2018 --> Jan 2019
- Provenge (sipuleucel-T) / Bausch Health
Enrollment change, Trial termination: Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=52, Terminated, Sponsor: Dendreon
Trial primary completion date: Jan 2018 --> Jan 2019 N=350 --> 52 | Recruiting --> Terminated; Administrative reasons
- || Provenge (sipuleucel-T) / Bausch Health
P2 data, Trial primary completion date: NCI-2014-00318: Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer (clinicaltrials.gov) - Jun 12, 2017
P2, N=54, Recruiting, Sponsor: University of California, San Francisco
N=350 --> 52 | Recruiting --> Terminated; Administrative reasons Trial primary completion date: Dec 2017 --> Dec 2018
- Provenge (sipuleucel-T) / Bausch Health
Trial termination, Metastases: Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (clinicaltrials.gov) - Jun 5, 2017
P2, N=8, Terminated, Sponsor: Dendreon
Trial primary completion date: Dec 2017 --> Dec 2018 Completed --> Terminated; Administrative reasons.
- | Provenge (sipuleucel-T) / Bausch Health
Journal: Immunotherapy for prostate cancer: False promises or true hope? (Pubmed Central) - May 24, 2017
Completed --> Terminated; Administrative reasons. However, apart from sipuleucel-T, prostate cancer has been conspicuously absent from the list of malignancies for which immunotherapies have received recent approval from the US Food and Drug Administration...Cancer 2016.
- | Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date, Metastases, Biopsy: Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - May 18, 2017
P1, N=20, Recruiting, Sponsor: Duke University
However, apart from sipuleucel-T, prostate cancer has been conspicuously absent from the list of malignancies for which immunotherapies have received recent approval from the US Food and Drug Administration...Cancer 2016. Trial primary completion date: Dec 2018 --> Dec 2019
- Provenge (sipuleucel-T) / Bausch Health, Tecentriq (atezolizumab) / Roche
Enrollment open, Metastases: Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer (clinicaltrials.gov) - May 3, 2017
P1, N=34, Recruiting, Sponsor: University of Hawaii
Trial primary completion date: Dec 2018 --> Dec 2019 Not yet recruiting --> Recruiting
- ||| Provenge (sipuleucel-T) / Bausch Health
Trial completion, Enrollment change, Metastases: PROCEED: A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Apr 24, 2017
P=N/A, N=1973, Completed, Sponsor: Dendreon
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | N=1500 --> 1973
- | Provenge (sipuleucel-T) / Bausch Health, Yervoy (ipilimumab) / Ono Pharma, BMS
Journal: Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer. (Pubmed Central) - Apr 2, 2017
In this small trial, the addition of IPI to SIP-T was well tolerated. IPI increased immunoglobulins specific for the PA2024 protein and PAP above the level achieved with SIP-T alone.
- | Provenge (sipuleucel-T) / Bausch Health, MVI-816 / Madison Vaccines
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer (clinicaltrials.gov) - Mar 3, 2017
P2, N=18, Active, not recruiting, Sponsor: University of Wisconsin, Madison
IPI increased immunoglobulins specific for the PA2024 protein and PAP above the level achieved with SIP-T alone. Recruiting --> Active, not recruiting | N=30 --> 18 | Trial primary completion date: Dec 2016 --> May 2017
- Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date, Metastases: Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (clinicaltrials.gov) - Jan 30, 2017
P2, N=50, Active, not recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting | N=30 --> 18 | Trial primary completion date: Dec 2016 --> May 2017 Trial primary completion date: Jun 2017 --> Jan 2018
- Provenge (sipuleucel-T) / Bausch Health
Trial completion: Immune Monitoring on Sipuleucel-T (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=36, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Jun 2017 --> Jan 2018 Active, not recruiting --> Completed
- Provenge (sipuleucel-T) / Bausch Health
Enrollment open, Trial initiation date, PD(L)-1 Biomarker, IO biomarker, Tumor cell, Metastases: CTC Immune Checkpoint (clinicaltrials.gov) - Jan 4, 2017
P=N/A, N=40, Recruiting, Sponsor: Duke University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Nov 2016
- Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date, Metastases, Biopsy: Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Nov 29, 2016
P1, N=20, Recruiting, Sponsor: Duke University
Not yet recruiting --> Recruiting | Initiation date: Jul 2016 --> Nov 2016 Trial primary completion date: Dec 2017 --> Dec 2018
- Provenge (sipuleucel-T) / Bausch Health, indoximod (NLG8189) / Lumos Pharma
Enrollment closed, Metastases: Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer (clinicaltrials.gov) - Nov 8, 2016
P2, N=47, Active, not recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting
- Provenge (sipuleucel-T) / Bausch Health
Trial initiation date, Trial primary completion date: Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Oct 11, 2016
P2, N=32, Not yet recruiting, Sponsor: The University of Texas Health Science Center, Houston
Recruiting --> Active, not recruiting Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Dec 2017 --> Jul 2018
- Provenge (sipuleucel-T) / Bausch Health
Trial initiation date, Trial primary completion date, Metastases: Docetaxel Followed by Provenge in Metastatic Prostate Cancer (clinicaltrials.gov) - Oct 11, 2016
P2, N=32, Not yet recruiting, Sponsor: The University of Texas Health Science Center, Houston
Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Dec 2017 --> Jul 2018 Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Dec 2017 --> Jul 2018
- Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date, Metastases, Biopsy: Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Jul 19, 2016
P1, N=20, Recruiting, Sponsor: Duke University
Initiation date: Jul 2016 --> Dec 2016 | Trial primary completion date: Dec 2017 --> Jul 2018 Trial primary completion date: Dec 2016 --> Dec 2017
- | Provenge (sipuleucel-T) / Bausch Health
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T (clinicaltrials.gov) - Jul 14, 2016
P2, N=20, Active, not recruiting, Sponsor: 21st Century Oncology
Trial primary completion date: Dec 2016 --> Dec 2017 Recruiting --> Active, not recruiting | N=100 --> 20 | Trial primary completion date: Jun 2016 --> Jun 2017
- pidilizumab (CT-011) / CureTech, Provenge (sipuleucel-T) / Bausch Health
Trial suspension, Metastases: Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer (clinicaltrials.gov) - Jun 29, 2016
P2, N=57, Suspended, Sponsor: Georgia Regents University
Recruiting --> Active, not recruiting | N=100 --> 20 | Trial primary completion date: Jun 2016 --> Jun 2017 Recruiting --> Suspended
- Provenge (sipuleucel-T) / Bausch Health
New P2 trial: Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer (clinicaltrials.gov) - Jun 9, 2016
P2, N=32, Not yet recruiting, Sponsor: The University of Texas Health Science Center, Houston
- Provenge (sipuleucel-T) / Bausch Health
New P2 trial, Metastases: Docetaxel Followed by Provenge in Metastatic Prostate Cancer (clinicaltrials.gov) - Jun 9, 2016
P2, N=32, Not yet recruiting, Sponsor: The University of Texas Health Science Center, Houston
- || Provenge (sipuleucel-T) / Bausch Health
P2 data, Trial primary completion date: NCI-2014-00318: Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer (clinicaltrials.gov) - May 25, 2016
P2, N=54, Recruiting, Sponsor: University of California, San Francisco
Recruiting --> Suspended Trial primary completion date: Jun 2016 --> Dec 2017
- Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Tumor cell, Metastases: CTC Immune Checkpoint (clinicaltrials.gov) - May 18, 2016
P=N/A, N=40, Not yet recruiting, Sponsor: Duke University
Trial primary completion date: Jun 2016 --> Dec 2017 Trial primary completion date: Jun 2017 --> Jan 2018
- Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date: Immune Monitoring on Sipuleucel-T (clinicaltrials.gov) - Mar 10, 2016
P=N/A, N=36, Active, not recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Jun 2017 --> Jan 2018 Trial primary completion date: Dec 2015 --> Dec 2016
- Provenge (sipuleucel-T) / Bausch Health
Trial initiation date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker, Tumor cell, Metastases: CTC Immune Checkpoint (clinicaltrials.gov) - Mar 8, 2016
P=N/A, N=40, Not yet recruiting, Sponsor: Duke University
Trial primary completion date: Dec 2015 --> Dec 2016 Initiation date: Oct 2015 --> May 2016 | Trial primary completion date: Jan 2017 --> Jun 2017
- Provenge (sipuleucel-T) / Bausch Health, indoximod (NLG8189) / Lumos Pharma
Trial primary completion date, Metastases: Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer (clinicaltrials.gov) - Feb 21, 2016
P2, N=50, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Initiation date: Oct 2015 --> May 2016 | Trial primary completion date: Jan 2017 --> Jun 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- Xtandi (enzalutamide capsule) / Pfizer, Astellas, Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date, Metastases: PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge (clinicaltrials.gov) - Feb 3, 2016
P0, N=67, Recruiting, Sponsor: Duke University
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Jun 2016 --> Dec 2018
- Provenge (sipuleucel-T) / Bausch Health
Enrollment closed, Metastases: Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (clinicaltrials.gov) - Jan 30, 2016
P2, N=50, Active, not recruiting, Sponsor: City of Hope Medical Center
Trial primary completion date: Jun 2016 --> Dec 2018 Recruiting --> Active, not recruiting
- Provenge (sipuleucel-T) / Bausch Health
Preclinical, Enrollment change, Trial termination, Metastases: PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Dec 14, 2015
P=N/A, N=10, Terminated, Sponsor: New York University School of Medicine
Recruiting --> Active, not recruiting N=20 --> 10 | Active, not recruiting --> Terminated; Due to PI leaving the institution
- Provenge (sipuleucel-T) / Bausch Health, Xofigo (radium Ra-223 dichloride) / Bayer
Enrollment open, Trial initiation date, Metastases: Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC (clinicaltrials.gov) - Dec 14, 2015
P2, N=34, Recruiting, Sponsor: Johns Hopkins University
N=20 --> 10 | Active, not recruiting --> Terminated; Due to PI leaving the institution Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Dec 2015
- |||| Provenge (sipuleucel-T) / Bausch Health
Trial completion, Metastases: ProACT: To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen (clinicaltrials.gov) - Oct 26, 2015
P2, N=122, Completed, Sponsor: Dendreon
Not yet recruiting --> Recruiting | Initiation date: Jul 2015 --> Dec 2015 Active, not recruiting --> Completed
- Provenge (sipuleucel-T) / Bausch Health, indoximod (NLG8189) / Lumos Pharma
Trial primary completion date, Metastases: Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer (clinicaltrials.gov) - Oct 22, 2015
P2, N=50, Recruiting, Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Dec 2015
- || Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date: Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T (clinicaltrials.gov) - Oct 8, 2015
P=N/A, N=350, Recruiting, Sponsor: Dendreon
Trial primary completion date: Jul 2015 --> Dec 2015 Trial primary completion date: Dec 2015 --> Jan 2022
- || Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date, Metastases: PROCEED: A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (clinicaltrials.gov) - Oct 8, 2015
P=N/A, N=1500, Active, not recruiting, Sponsor: Dendreon
Trial primary completion date: Dec 2015 --> Jan 2022 Trial primary completion date: Dec 2015 --> Jan 2017
- |||| Provenge (sipuleucel-T) / Bausch Health
Trial completion, Metastases: Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer (clinicaltrials.gov) - Oct 8, 2015
P2, N=91, Completed, Sponsor: Dendreon
Trial primary completion date: Dec 2015 --> Jan 2017 Active, not recruiting --> Completed
- || Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date, Metastases: STAMP: Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer (clinicaltrials.gov) - Oct 7, 2015
P2, N=69, Active, not recruiting, Sponsor: Dendreon
Active, not recruiting --> Completed Trial primary completion date: Jul 2015 --> Feb 2016
- ||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, Provenge (sipuleucel-T) / Bausch Health
Enrollment change, Trial primary completion date, Metastases: STRIDE: A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer (clinicaltrials.gov) - Oct 7, 2015
P2, N=52, Active, not recruiting, Sponsor: Dendreon
Trial primary completion date: Jul 2015 --> Feb 2016 N=100 --> 52 | Trial primary completion date: Sep 2015 --> Jul 2017
- Provenge (sipuleucel-T) / Bausch Health
Trial completion, Enrollment change, Trial primary completion date, Metastases: Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (clinicaltrials.gov) - Oct 7, 2015
P2, N=8, Completed, Sponsor: Dendreon
N=100 --> 52 | Trial primary completion date: Sep 2015 --> Jul 2017 Active, not recruiting --> Completed | N=90 --> 8 | Trial primary completion date: Mar 2017 --> Apr 2015
- ||||||| Provenge (sipuleucel-T) / Bausch Health
Trial completion, Metastases: PROTECT: PROvenge Treatment and Early Cancer Treatment (clinicaltrials.gov) - Oct 7, 2015
P3, N=176, Completed, Sponsor: Dendreon
Active, not recruiting --> Completed | N=90 --> 8 | Trial primary completion date: Mar 2017 --> Apr 2015 Active, not recruiting --> Completed
- Provenge (sipuleucel-T) / Bausch Health
Enrollment closed, Preclinical, Trial primary completion date, Metastases: PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Sep 29, 2015
P=N/A, N=20, Active, not recruiting, Sponsor: New York University School of Medicine
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> May 2015
- Provenge (sipuleucel-T) / Bausch Health
Trial initiation date, PD(L)-1 Biomarker, IO biomarker, Tumor cell, Metastases: CTC Immune Checkpoint (clinicaltrials.gov) - Sep 16, 2015
P=N/A, N=40, Not yet recruiting, Sponsor: Duke University
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> May 2015 Initiation date: Jul 2015 --> Oct 2015
- Provenge (sipuleucel-T) / Bausch Health, tasquinimod (ABR-215050) / Active Biotech, Ipsen
Enrollment closed, Enrollment change, Metastases: Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - Aug 13, 2015
P2, N=2, Active, not recruiting, Sponsor: Roswell Park Cancer Institute
Initiation date: Jul 2015 --> Oct 2015 Recruiting --> Active, not recruiting | N=60 --> 2
- Provenge (sipuleucel-T) / Bausch Health
Enrollment closed: Immune Monitoring on Sipuleucel-T (clinicaltrials.gov) - Jul 10, 2015
P=N/A, N=36, Active, not recruiting, Sponsor: Icahn School of Medicine at Mount Sinai
Recruiting --> Active, not recruiting | N=60 --> 2 Recruiting --> Active, not recruiting
- Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date, Metastases: Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer (clinicaltrials.gov) - Jun 12, 2015
P2, N=50, Recruiting, Sponsor: City of Hope Medical Center
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Jun 2017
- | Provenge (sipuleucel-T) / Bausch Health, Xofigo (radium Ra-223 dichloride) / Bayer
New P2 trial, Metastases: Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC (clinicaltrials.gov) - Jun 4, 2015
P2, N=34, Not yet recruiting, Sponsor: Johns Hopkins University
- Provenge (sipuleucel-T) / Bausch Health
New trial, PD(L)-1 Biomarker, IO biomarker, Tumor cell, Metastases: CTC Immune Checkpoint (clinicaltrials.gov) - May 28, 2015
P=N/A, N=40, Not yet recruiting, Sponsor: Duke University
- ||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, Provenge (sipuleucel-T) / Bausch Health
Enrollment open, Metastases: PEAX: Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge (clinicaltrials.gov) - May 21, 2015
P0, N=67, Recruiting, Sponsor: Duke University
Trial primary completion date: Jun 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- Provenge (sipuleucel-T) / Bausch Health
Trial primary completion date, Metastases: Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC) (clinicaltrials.gov) - May 8, 2015
P2, N=41, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2015 --> Dec 2016